RAL-eve Study: Raltegravir Substitution Study

HIV Infections Clinical Trial

Official title:

Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00523237
• Other study ID #: RAL-eve study
• Status: Completed
• Phase: N/A
• First received: August 29, 2007
• Last updated: October 31, 2011
• Start date: October 2007
• Est. completion date: December 2010

Study information

• Verified date: October 2011
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to:

• Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide,

• Monitor the safety and efficacy of raltegravir, and

• Assess the change in quality of life in patients who have switched from Enfuvirtide to raltegravir

Description:

We enrolled virologically suppressed HIV-1 infected patients with injection site reactions for a switch from enfuvirtide to raltegravir. At baseline, enfuvirtide was switched to raltegravir without additional changes to the antiretroviral regimen allowed. Viral load, T-cells, and toxicity were evaluated at baseline, 2, 4, 12 and 24 weeks. Adherence and injection site reactions were evaluated at baseline, 4, 12 and 24 weeks. The single-copy assay was used to measure HIV RNA levels at screening, baseline and at 12 and 24 weeks.

Other known NCT identifiers

• NCT00627939

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: December 2010
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.

2. ART for at least 6 months prior to study entry with a regimen that includes enfuvirtide.

3. Self-defined infusion site reaction to enfuvirtide (usually will be painful inflammatory nodules)

4. No change in ART regimen for at least 3 months prior to study entry.

5. CD4+ cell count >50/mm3 at screening (obtained within 60 days prior to study entry).

6. Documentation of HIV-1 RNA below the limit of quantification of an ultrasensitive assay

7. All HIV-1 RNA levels obtained within 6 months prior to study entry are below the limits of quantification on all tests, except as explained above in section 4.1.6 for a single detectable viral load of <50 copies but <200 copies in last 6 months.

8. Laboratory values obtained within 60 days prior to entry:

• Absolute neutrophil count (ANC) >750/mm3

• Hemoglobin >9.0 g/dL for female subjects and>10.0 g/dL for male subjects

• Platelet count >50,000/mm3

• Calculated creatinine clearance (CrCl) >30 mL/min, as estimated by the Cockcroft-Gault equation*

• AST (SGOT), ALT (SGPT), and alkaline phosphatase <5 x ULN

• Total bilirubin <2.5 x ULN. If the subject is taking an indinavir- or atazanavir-containing regimen at the time of screening, total bilirubin <5 x ULN is acceptable.

9. For females of reproductive potential will need a negative serum or urine pregnancy test within 48 hours prior to entry.

10. Men and women age >18 years.

11. Ability and willingness of subject to provide informed consent.

Exclusion Criteria:

1. Unstable clinical condition, such as unstable cardiac disease, or cancer requiring ongoing chemotherapy or radiation therapy, or other medical condition which, in the opinion of the investigator, would preclude a subject from safely undergoing study procedures.

2. Breast-feeding or pregnancy.

3. An opportunistic infection within 60 days prior to entry.

4. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.

5. Active drug or alcohol use or dependence that, in the opinion of the Protocol Director, would interfere with adherence to study requirements.

6. Receipt of a non-HIV vaccination within 30 days prior to study entry or plan for receipt of vaccination during the study.

7. Plan to change the background ART within 24 weeks after study entry.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Raltegravir
400 mg Twice daily for 24 weeks

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Cl — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percentage of Patients Who Maintain a Viral Load < 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir	evaluate the percent of patients with viral load of <50 copies at week 24 of study after being switched from enfuvirtide to raltegravir	24 weeks	No